European Medicines Agency recommends refusal of the marketing authorisation for masitinib

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product masitinib (Masican), intended for the treatment of malignant gastrointestinal stromal tumour (GIST). Read more here.